Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Immunome, Inc.NASDAQ: IMNM

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit turns positive

Q3 FY2026 gross profit was $0, compared with -$49.19M a year earlier. Trailing-twelve-month gross profit was -$753K.

Context

  • Gross profit amounted to 57.4% of revenue in FY2025, down 42.6 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$188.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$3.99M-55.9% YoY
LTMSep 2026
-$753K+98.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-55.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
3.99M USD
Year-over-year change
-55.9%

Gross Profit vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +98.1% is the 2nd highest of 7, against a peer median of +34.2%.
IMNM Competitors
Gross Profit for IMNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026$381.15M USD+15.4%+28.0%98.8%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M USD+52.1%+17.0%98.7%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-9.9%100.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K USD———
IMMXImmix Biopharma, Inc.LTM Mar 2026-$130.77K USD———
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$742K USD+99.6%—662.5%
IMNMImmunome, Inc.LTM Sep 2026-$753K USD+98.1%——
BCYCBicycle Therapeutics plcLTM Mar 2026-$7.53M USD+94.3%+71.2%11.9%
Peer median (excluding IMNM) —+34.2%+17.0%98.8%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.